SWI/SNF Chromatin Remodeling Loss and Human Cancer

SWI/SNF 染色质重塑损失与人类癌症

基本信息

  • 批准号:
    7267012
  • 负责人:
  • 金额:
    $ 27.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-08-15 至 2009-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The identification of tumor suppressor genes has led to new insights into the mechanisms of human cancer development. The normal functions of these genes often lie in the control of gene expression, especially in the realm of cell cycle control and cellular differentiation. Several recent studies have implicated aberrant activity of chromatin remodeling complexes in the development of human cancer. Mutations in the INI1/SNF5 gene, a component of the SWI/SNF chromatin remodeling complex, occur in the majority of malignant rhabdoid tumors. The SWI/SNF complex acts as a global transcriptional activator that alters nucleosome positioning on DNA via an energy-dependent mechanism. Others and we have also demonstrated the loss and/or mutations of both human SWI2 homologs, BRG1 and BRM, in human tumor cell lines and primary tumors. Loss of expression of both proteins abrogates Rb-mediated cell cycle arrest. However either protein appears to regulate the expression of key cancer progression genes including Ecadherin and CD44. Furthermore, while BRG1v/- mice develop adenocarcinomas, BRM-/- mice do not show an increased tumor incidence. Therefore, the mechanism by which loss of expression of either or both proteins contributes to the etiology of human cancers remains unresolved. We have observed an association between BRG1-induced gene expression and loss of promoter methylation in human tumor cells, especially Non-Small Cell Lung Carcinomas (NSCLC). Based on these studies, we hypothesize that loss of SWI/SNF complex activity through inactivation of BRG1 and/or BRM fuels genomic instability during human tumor progression by facilitating gene silencing through DNA methylation. To test this hypothesis, we require a better understanding how loss of expression of BRG1 and BRM proteins alters the biological properties of tumor cells and the chromatin structure of cancer related genes. In this application, we will identify overlapping and independent biological and biochemical functions of these proteins in the first specific aim. In the second specific aim, we will determine how the loss of these proteins contributes to lung tumor development using a human tracheobronchial cell culture model. In the last specific aim, we will characterize the effects of BRG1 and BRM loss on the chromatin structure and DNA methylation status of important target genes. The dissection of the role of these genes in human cancer development will broaden our understanding of their normal biological and biochemical functions, provide new insights into the control of DNA methylation and impact upon treatment and detection of this clinically important tumor.
描述(由申请人提供):肿瘤抑制基因的鉴定导致了对人类癌症发展机制的新见解。这些基因的正常功能通常在于控制基因表达,特别是在细胞周期控制和细胞分化领域。最近的几项研究表明,染色质重塑复合物的异常活性与人类癌症的发生有关。INI 1/SNF 5基因突变是SWI/SNF染色质重塑复合物的一个组成部分,发生在大多数恶性横纹肌样肿瘤中。SWI/SNF复合物作为一种全局转录激活因子,通过能量依赖机制改变核小体在DNA上的定位。其他人和我们也证明了人SWI 2同源物BRG 1和BRM在人肿瘤细胞系和原发性肿瘤中的缺失和/或突变。这两种蛋白质表达的缺失消除了Rb介导的细胞周期停滞。然而,这两种蛋白质似乎都调节关键癌症进展基因的表达,包括E钙粘蛋白和CD 44。此外,虽然BRG 1v/-小鼠发生腺癌,但BRM-/-小鼠没有显示出肿瘤发病率增加。因此,其中一种或两种蛋白质的表达缺失导致人类癌症病因学的机制仍未得到解决。我们已经观察到BRG 1诱导的基因表达与人类肿瘤细胞,特别是非小细胞肺癌(NSCLC)中启动子甲基化缺失之间的关联。基于这些研究,我们假设SWI/SNF复合物活性的丧失通过BRG 1和/或BRM的失活通过DNA甲基化促进基因沉默而在人类肿瘤进展期间加剧基因组不稳定性。为了验证这一假设,我们需要更好地了解BRG 1和BRM蛋白表达的缺失如何改变肿瘤细胞的生物学特性和癌症相关基因的染色质结构。在本申请中,我们将在第一个具体目标中鉴定这些蛋白质的重叠和独立的生物学和生物化学功能。在第二个具体目标中,我们将使用人气管支气管细胞培养模型确定这些蛋白质的丢失如何促进肺肿瘤的发展。在最后一个具体的目标,我们将描述的影响,BRG 1和BRM损失的染色质结构和DNA甲基化状态的重要靶基因。这些基因在人类癌症发展中的作用的解剖将拓宽我们对其正常生物学和生化功能的理解,提供新的见解DNA甲基化的控制和对治疗和检测这种临床上重要的肿瘤的影响。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bernard E. Weissman其他文献

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type
超级增强子与雷公藤甲素在卵巢高钙血症型小细胞癌中的疗效
  • DOI:
    10.1016/j.isci.2025.111770
  • 发表时间:
    2025-02-21
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Jessica D. Lang;William Selleck;Shawn Striker;Nicolle A. Hipschman;Rochelle Kofman;Anthony N. Karnezis;Felix K.F. Kommoss;Friedrich Kommoss;Jae Rim Wendt;Salvatore J. Facista;William P.D. Hendricks;Krystal A. Orlando;Patrick Pirrotte;Elizabeth A. Raupach;Victoria L. Zismann;Yemin Wang;David G. Huntsman;Bernard E. Weissman;Jeffrey M. Trent
  • 通讯作者:
    Jeffrey M. Trent
Mutant Nrf2supE79Q/sup enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors
突变的NRF2SUPE79Q/SUP增强了致癌性Ras角质形成细胞和皮肤肿瘤的促进和进展
  • DOI:
    10.1016/j.redox.2024.103261
  • 发表时间:
    2024-09-01
  • 期刊:
  • 影响因子:
    11.900
  • 作者:
    John G. Witherspoon;Jonathan R. Hall;Dereje Jima;Hannah M. Atkins;Nathan T. Wamsley;Michael B. Major;Bernard E. Weissman;Robert C. Smart
  • 通讯作者:
    Robert C. Smart
SNF5/INI1 Deficiency Destabilizes the SWI/SNF Complex During Malignant Rhabdoid Tumor Development
  • DOI:
    10.1016/j.cancergen.2014.09.007
  • 发表时间:
    2014-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yasumichi Kuwahara;Darmood Wei;Shujie Song;Courtney Cannon;Donastas Sakellariou-Thompson;Michael Emanuele;Hajime Hosoi;Bernard E. Weissman
  • 通讯作者:
    Bernard E. Weissman

Bernard E. Weissman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bernard E. Weissman', 18)}}的其他基金

Cancer Epigenetics Training Grant
癌症表观遗传学培训补助金
  • 批准号:
    9977976
  • 财政年份:
    2017
  • 资助金额:
    $ 27.49万
  • 项目类别:
Cancer Epigenetics Training Grant
癌症表观遗传学培训补助金
  • 批准号:
    9756152
  • 财政年份:
    2017
  • 资助金额:
    $ 27.49万
  • 项目类别:
Cancer Epigenetics Training Grant
癌症表观遗传学培训补助金
  • 批准号:
    10240322
  • 财政年份:
    2017
  • 资助金额:
    $ 27.49万
  • 项目类别:
Animal Models Core Facility
动物模型核心设施
  • 批准号:
    8340285
  • 财政年份:
    2011
  • 资助金额:
    $ 27.49万
  • 项目类别:
Role of hsnf5/BAF47 Loss in Human Cancer Development
hsnf5/BAF47 缺失在人类癌症发展中的作用
  • 批准号:
    8322896
  • 财政年份:
    2011
  • 资助金额:
    $ 27.49万
  • 项目类别:
SWI/SNF complex loss facilitates gene silencing during NSCLC development
SWI/SNF 复合物丢失促进 NSCLC 发展过程中的基因沉默
  • 批准号:
    7635080
  • 财政年份:
    2009
  • 资助金额:
    $ 27.49万
  • 项目类别:
CORE--ANIMAL PROCEDURES
核心——动物程序
  • 批准号:
    7100664
  • 财政年份:
    2004
  • 资助金额:
    $ 27.49万
  • 项目类别:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
SWI/SNF 染色质重塑损失与人类癌症
  • 批准号:
    6681590
  • 财政年份:
    2003
  • 资助金额:
    $ 27.49万
  • 项目类别:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
SWI/SNF 染色质重塑损失与人类癌症
  • 批准号:
    6790490
  • 财政年份:
    2003
  • 资助金额:
    $ 27.49万
  • 项目类别:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
SWI/SNF 染色质重塑损失与人类癌症
  • 批准号:
    7098021
  • 财政年份:
    2003
  • 资助金额:
    $ 27.49万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 27.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了